# Michael May President and Chief Executive Officer, CCRM



Michael May is President and CEO of the Centre for Commercialization of Regenerative Medicine (CCRM), a Canadian not-for-profit that develops technologies, launches new companies, and catalyzes investment in the field of regenerative medicine, including cell and gene therapy. Prior to CCRM, Michael was the President and co-founder of Rimon Therapeutics Ltd., a Toronto-based tissue engineering company developing novel medical polymers that possess drug-like activity.

Michael sits on a number of boards and advisory committees including OmniaBio Inc.; the Foundation for Cell & Gene Medicine; AgeX Corporation; panCELLa Inc.; CCRM Enterprises; the International Advisory Board of the Swedish Centre for Advanced Medical Products (CAMP); the Poietis SAB; the Entrepreneurship Leadership Council at the University of Toronto; the Cell and Gene Therapy Insights Editorial Advisory Board; and, the Commercialization Committee of the International Society for Cell and Gene Therapy. He is the Chairman of ExCellThera Ltd.

Michael completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship. Michael received the 2023 Le Prix Luc Sensebé Innovation and Leadership Award from the International Society for Cell and Gene Therapy.

#### *Connect with Dr. May:*



Media Contact: Stacey Johnson, Vice President, Communications and Marketing E: <u>stacey.johnson@ccrm.ca</u>; T: 647-309-1830



## Peter Zandstra C.M. Chief Scientific Officer, CCRM



Peter Zandstra graduated with a Bachelor of Engineering degree from McGill University in the Department of Chemical Engineering, obtained his PhD degree from the University of British Columbia (UBC) in the Department of Chemical Engineering and Biotechnology and continued his research training as a post-doctoral fellow in the field of Bioengineering at the Massachusetts Institute of Technology.

Peter is the Chief Scientific Officer for CCRM, the Founding Director of the School of Biomedical Engineering at UBC, and the Director of the Michael Smith Laboratories at UBC. Peter holds an academic appointment as a Professor at the University of Toronto's Institute of Biomaterials and Biomedical Engineering. In 2020, Peter was named a Fellow of the Canadian Academy of Health Sciences. Also, Peter is the Canada Research Chair in Stem Cell Bioengineering and is a recipient of a number of awards and fellowships including the Premiers Research Excellence Award (2002), the E.W.R. Steacie Memorial Fellowship (2006), the John Simon Guggenheim Memorial Foundation Fellowship (2007), Canada's Top 40 Under 40 (2008), the University of Toronto's McLean Award (2009) and the Till and McCulloch Award (2013). Peter is also a fellow of the American Institute for Medical and Biological Engineering, the American Association for the Advancement of Science and the Royal Society of Canada. In January, 2022, Peter was appointed Member of the Order of Canada (C.M.), one of Canada's highest civic honours.

Peter's research focuses on understanding how complex communication networks between stem cells and their progeny influence self-renewal and differentiation, and how this information can be applied to the design of novel culture technologies capable of controlling cell fate.

#### Connect with Dr. Zandstra:



Photo credit: Paul Joseph

Media Contact: Stacey Johnson, Vice President, Communications and Marketing E: <u>stacey.johnson@ccrm.ca</u>; T: 647-309-1830



## Michael Nobrega Chair, Board of Directors, CCRM



Michael Nobrega has been Chair of the Board of Directors of Ontario Centres of Excellence (OCE) since 2012, previously serving as a member since 2007. He is former President and CEO of the Ontario Municipal Employees Retirement System (OMERS), one of Canada's largest pension plans with more than \$95 billion in assets. In mid-2014, Mr. Nobrega was appointed to chair of the Expert Panel on the restructuring and refinancing of the 750,000 square feet of the MaRS West Tower in the MaRS Discovery District in Toronto. He was also appointed by the provincial government as chair of the Expert Panel on the refurbishment of the 1.2 million square feet MacDonald block in downtown Toronto. A veteran financial and investment executive with more than 30 years' experience, he previously served as President and CEO of OMERS' wholly owned subsidiary, Borealis Infrastructure Management Inc., an investment entity that originated and structured infrastructure investments for the OMERS pension fund. Prior to Borealis, Mr. Nobrega was a tax partner at Arthur Andersen, a major international accounting firm.

Mr. Nobrega holds an Honours BA from the University of Toronto. He also holds a chartered accountancy designation from the Institute of Chartered Accountants of Ontario and the Canadian Institute of Chartered Accountants. In 2009, Mr. Nobrega was named a Fellow of the Institute by the Institute of Chartered Accountants of Ontario.



### Get to Know CCRM's Employees



CCRM has nearly 240 employees, including our Cytiva colleagues. Many are pictured above. Approximately 60 per cent of its employees are women. Over half of CCRM's employees are fluent in languages other than English, including French, Spanish, Hindi, Cantonese, Mandarin, Korean, Ukrainian, Russian, Arabic, Irish, Italian, Serbian, Greek, Danish and many more.

Seventy-five per cent of CCRM's employees have science, technology, engineering and mathematics (STEM) education backgrounds. Forty-two per cent are scientists, and 10 per cent are engineers.

The majority of CCRM's employees have advanced degrees. Ninety employees have a master's degree or MBA, and 57 employees have a PhD.

